Celerus Diagnostics today announced the appointment of Dr. Marc Key as Chief Scientific Officer. The rapid cancer diagnostics company expanded its management team in anticipation of an exciting year of growth and innovation.
“We are extremely pleased to have Marc join our team,” said Michael Sarrasin, CEO. “His experience and technical expertise bring valuable insight to the company.” Responsible for new product development, Dr. Key will provide direction in the creation of next generation diagnostic tools.
With over 25 years of experience in research, development, and product development, Dr. Key has held senior positions with companies such as Dako Corporation and Biogenix Corporation. He has also retained various academic appointments and positions at The National Cancer Institute, Harvard Medical School, State University of New York and the University of South Carolina.
“Celerus is a company with tremendous technology; I look forward to building on what is already an incredible product,” said Dr. Key. “Providing rapid response for patients combined with the ability to create a more efficient lab is the future of anatomic pathology.”
Dr. Key holds a BS from Iowa State University, an MS from the University of Montana, and a PhD from the Medical University of South Carolina.
About Celerus:
Founded in 2004 in Santa Barbara, California, Celerus Diagnostics is committed to enhancing the diagnostic capabilities of the pathology laboratory. Celerus technology provides the capability to decentralize testing, and move results closer to the patient for real time decision making. For more information, please visit our website: www.celerusdiagnostics.com or contact us at 805.685.0797.
This release contains forward-looking statements that involve risks and uncertainties, including, but not limited to, Celerus Diagnostics’ ability to successfully complete its development program, competitive pressures and other factors such as the introduction or regulatory approval of new products by our competitors and pricing of competing products and the resulting effects on sales and pricing of our products, disruptions or other problems with our sources of supply, significant product liability or other claims, difficulties with new product development and market acceptance, changes in the mix of our products sold, patent conflicts, product recalls, United States Food and Drug Administration (FDA) delay in or approval or rejection of new or existing products, changes in Medicare, Medicaid or third-party reimbursement policies, changes in government regulation, use of hazardous or environmentally sensitive materials, our inability to implement new information technology systems, our inability to integrate new acquisitions, and other events. This press release reflects information as of the date of this press release, and the company takes no responsibility in updating the information contained herein now or in the future.
Comments